Frontiers in Pharmacology (Mar 2025)

When HERG-caused LQT2 encounters antisense oligonucleotide: is exon 6 skipping therapy plausible?

Zequn Zheng,
Zequn Zheng,
Yongfei Song

Affiliations

Zequn Zheng: Ningbo Institute of Innovation for Combined Medicine and Engineering, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China
Zequn Zheng: Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Yongfei Song: Ningbo Institute of Innovation for Combined Medicine and Engineering, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China

DOI: https://doi.org/10.3389/fphar.2025.1535259
Journal volume & issue: Vol. 16

Abstract

Graphical AbstractThe unique in‐frame exon 6 of the HERG gene as a potential target for antisense oligonucleotide‐mediated exon skipping therapy.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal